A Study to Evaluate Potential Cytochrome P450 and Transporter Protein Interactions With CC-99677
Status:
Completed
Trial end date:
2021-06-02
Target enrollment:
Participant gender:
Summary
It is a phase 1, open-label, single-center, three-part study to assess the safety,
tolerability, and pharmacokinetics of multiple doses of CC-99677 administered alone or in
combination with either methotrexate and sulfasalazine; itraconazole, rifampin, midazolam, or
a cocktail of digoxin, metformin, and rosuvastatin in healthy subjects